Uterine Fibroid Embolization Device Industry Analysis 2026-2033 | Market Size USD 412 Million, CAGR 6.8%, Regional Outlook | Companies: Boston Scientific, Merit Medical Systems, Terumo Corporation, Hologic, Cook Medical

The global uterine fibroid embolization device market was valued at USD 412 million in 2025 and is projected to reach USD 687 million by 2033, growing at a CAGR of 6.8% between 2026 and 2033. Uterine fibroid embolization devices, including embolic agents and delivery catheters, enable a minimally invasive alternative to hysterectomy and myomectomy by blocking blood supply to fibroids and reducing their size. Demand is climbing as rising fibroid prevalence among women of reproductive age coincides with growing patient and clinician preference for uterus-preserving, minimally invasive treatment options. Hospitals, ambulatory surgical centers, and interventional radiology practices represent the primary purchasers of this technology. Figures are based on DHR's proprietary market-sizing model, triangulating primary interviews, company filings, and trade data through Q2 2026.

Get a free sample report: https://datahorizzonresearch.com/request-sample-pdf/uterine-fibroid-embolization-device-market-76393

Uterine Fibroid Embolization Device Market: Key Facts

• Global market size was USD 412 million in 2025.
• Market is forecast to reach USD 687 million by 2033.
• CAGR of 6.8% expected between 2026 and 2033.
• Microsphere embolic agents hold the largest procedure share.
• Uterine artery embolization leads among minimally invasive fibroid treatments.
• North America holds the largest current regional market share.
• Asia-Pacific is the fastest-growing region for market expansion.
• Hospitals remain the dominant end-user segment by procedure volume.
• Adoption of uterine artery embolization grew meaningfully in recent years.
• Ambulatory surgical center procedures are an accelerating growth segment.
• Key players include Boston Scientific, Merit Medical Systems, Terumo Corporation, Hologic, and Cook Medical.

What Is Uterine Fibroid Embolization and How Has the Market Evolved?

Uterine fibroid embolization is a radiology-guided procedure that blocks blood supply to uterine fibroids using embolic agents delivered through catheters, causing fibroids to shrink without surgical removal of the uterus. The market ecosystem spans medical device manufacturers producing embolic microspheres and delivery systems, interventional radiologists performing procedures, and hospitals and surgical centers where treatment is administered. The category has evolved substantially from early PVA particle-based embolization toward more precisely calibrated microsphere technology, which physicians increasingly prefer for improved procedural consistency. Pricing reflects the specialized nature of embolic agents and delivery catheters, with newer transcervical embolization systems commanding a premium over traditional femoral-access approaches. Regulatory oversight through the FDA and equivalent international bodies continues to shape product approval pathways, while growing patient demand for uterus-preserving alternatives to hysterectomy continues reshaping treatment guidelines and reimbursement policies.

How Is the Market Segmented?

By Device Type
o Microcatheters (advancing rapidly from 22% to 31% share by 2033)
o Coaxial Catheter Systems (emerging, 5% share)
o Flow-Directed Delivery Systems (pre-commercial, expected to enter 2027-2029)

By Embolic Agent
o Spherical Polyvinyl Alcohol (dominant, 45% share, flat growth)
o Calibrated Microspheres/Embospheres (fast-growing, 8.2% annual growth)
o Liquid Emboli/Polymers (emerging segment, under 3% share, high innovation intensity)

By End User
o Hospital Radiology Departments (63% share, declining to 58% by 2033)
o Ambulatory Surgery Centers (growing from 24% to 32% share)
o Specialty Fibroid Centers (new model, 2% share, expanding 12% annually)

By Region
o North America
o Europe
o Asia-Pacific
o Latin America
o Middle East & Africa

Where Is Demand Strongest by Region?

North America dominates the global market, supported by well-established healthcare infrastructure, high healthcare expenditure, and strong awareness of uterine fibroid treatment options among both patients and physicians. Europe represents the second-largest market, driven by similar factors including a well-developed healthcare system and supportive government reimbursement policies. Asia-Pacific is the fastest-growing region, propelled by expanding healthcare access, rising fibroid prevalence awareness, and accelerating adoption of minimally invasive treatment technology, particularly in India where local production initiatives have improved device affordability. Latin America and the Middle East and Africa remain smaller markets currently, with growth tied to gradually improving healthcare infrastructure and expanding access to interventional radiology services.

What's Driving Growth in This Market?

Rising prevalence of uterine fibroids among women of reproductive age is the foundational driver of embolization device demand. Growing patient and clinician preference for minimally invasive, uterus-preserving procedures over traditional hysterectomy continues to expand the treated population. Increasing demand among younger patients specifically seeking fertility-preserving fibroid treatment options is broadening the addressable market beyond older patient demographics. Rising adoption of procedures in ambulatory surgical center settings is improving accessibility and reducing overall treatment costs. Continued investment in advanced delivery catheters and embolic systems is enhancing procedural precision and driving physician confidence in embolization over surgical alternatives. DHR Analyst Insight: Manufacturers offering integrated systems combining precise embolic agents with next-generation transcervical delivery catheters are capturing stronger physician adoption than those competing on embolic agent technology alone.

What Emerging Trends and Opportunities Are Shaping the Industry?

Growing adoption of transcervical embolization systems offering improved procedural control is gaining momentum among interventional radiologists seeking greater precision. Increasing shift toward ambulatory surgical center procedures is reducing costs and improving patient convenience relative to traditional hospital-based treatment. Rising physician and patient interest in fertility-preserving treatment approaches is expanding embolization's appeal among younger patient populations. On the opportunity side, manufacturers investing in next-generation transcervical delivery technology can capture premium positioning as physicians increasingly prioritize procedural precision, while expansion into Asia-Pacific's rapidly growing healthcare infrastructure offers substantial volume growth potential for cost-competitive device manufacturers.

What Challenges Does the Market Face?

High costs associated with advanced embolization devices and delivery systems remain a barrier in developing healthcare markets with constrained reimbursement structures. Ongoing healthcare reform and reimbursement policy variability across different regions creates uncertainty for market growth projections. Competition from alternative minimally invasive treatments, including radiofrequency ablation and focused ultrasound systems, continues to fragment the broader fibroid treatment device market. Regulatory approval pathways for new embolic agent formulations can extend time-to-market for innovative products. DHR Strategic Perspective: Manufacturers with established reimbursement relationships and clinical outcome data are better positioned to defend market share against emerging alternative treatment modalities than newer entrants lacking long-term procedural evidence.

Competitive Landscape

The market features intense competition between established medical device manufacturers with comprehensive embolization portfolios and smaller specialized companies focused on niche embolic agent or delivery system innovation. Competitive intensity centers on procedural precision, delivery system innovation, and clinical outcome data rather than price alone. Leading players continue pursuing strategic acquisitions to expand minimally invasive treatment portfolios, as seen in recent consolidation activity within the broader fibroid treatment device space. DHR Competitive Intelligence: Expect continued M&A activity as larger medical device companies acquire specialized embolization and minimally invasive treatment technology firms to broaden their women's health portfolios.

Who Are the Top Companies in This Market?

1. Boston Scientific Corporation - Headquartered in the U.S., Boston Scientific is a leading embolization device manufacturer, known for biocompatible embolic agents and advanced delivery systems including its Sonata Elite transcervical system.

2. Merit Medical Systems - Based in the U.S., Merit Medical holds significant market share in embolic agents and delivery catheters, competing on procedural precision and established interventional radiology relationships.

3. Terumo Corporation - Headquartered in Japan, Terumo brings advanced medical device manufacturing expertise and a strong distribution network to its embolization product portfolio, emphasizing continuous R&D investment.

4. Hologic, Inc. - Based in the U.S., Hologic has expanded its minimally invasive women's health portfolio through strategic acquisitions, including its 2024 purchase of Gynesonics to broaden fibroid treatment offerings.

5. Cook Medical - Headquartered in the U.S., Cook Medical focuses on advanced embolization products and delivery systems, competing through continuous innovation in catheter-based treatment technology.

Recent Developments

Hologic completed its acquisition of Gynesonics for USD 350 million in October 2024, expanding its portfolio of minimally invasive fibroid treatment technology. Boston Scientific received FDA approval for its Sonata Elite transcervical embolization system, offering improved procedural control and precision. Several manufacturers have continued investing in next-generation delivery catheter technology to improve embolization precision and reduce procedure times. DHR Market Impact: These developments signal continued consolidation and innovation investment as manufacturers compete for share in the growing minimally invasive fibroid treatment segment through 2028.

What's the Future Outlook for This Market?

Expect Asia-Pacific to sustain the fastest growth trajectory through 2030 as healthcare infrastructure investment and rising fibroid treatment awareness continue expanding across India and other developing markets. Manufacturers investing in transcervical delivery technology are likely to gain preferential adoption as physicians prioritize procedural precision and control. Growing demand among younger, fertility-focused patients should continue broadening the treated population beyond traditional demographics. Consolidation among specialized embolization technology providers and larger medical device companies is likely to continue as women's health portfolios become an increasingly strategic acquisition target.

Latest Reports:

Kegs Market: https://datahorizzonresearch.com/kegs-market-21206
Cement Grinding Aids Market: https://datahorizzonresearch.com/cement-grinding-aids-market-21882
Automatic Center Grinding Machine Market: https://datahorizzonresearch.com/automatic-center-grinding-machine-market-22558
Wi-SUN Technology Market: https://datahorizzonresearch.com/wi-sun-technology-market-23234

Contact Information
Contact Name: Ajay N
Company: DataHorizzon Research
Phone: +1-970-633-3460
Email: sales@datahorizzonresearch.com

About us:

DataHorizzon is a market research and advisory company that assists organizations across the globe in formulating growth strategies for changing business dynamics. Its offerings include consulting services across enterprises and business insights to make actionable decisions. DHR's comprehensive research methodology for predicting long-term and sustainable trends in the market facilitates complex decisions for organizations.

This release was published on openPR.